Epidemiology of heart failure: Study of Heart failure in the Australian Primary carE setting (SHAPE)

Liew, Danny; Audehm, Ralph; Haikerwal, Deepak; Piazza, Peter; Neville, A. Munro; Lim, Kevin; Parsons, Richard; Sindone, Andrew

doi:10.1002/ehf2.12979

Cited by 9 publications

(8 citation statements)

References 8 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From this, the age-standardised prevalence and annual incidence of HF in the 'active' population were calculated to be 2.20% (95% confidence interval [CI]: 2.17, 2.23) and 0.348% (95% CI: 0.342, 0.354). 12 We are confident that the results are representative of the epidemiology in the Australian community setting. The key word search was conducted on the medical records of 1.93 million adult Australiansover 10% of the adult population.…”

Section: Resultsmentioning

confidence: 79%

Healthcare services use by patients with heart failure in Australia: Findings from the SHAPE study

Audehm

Neville²,

Piazza³

et al. 2022

Aust J Gen Pract

Self Cite

View full text Add to dashboard Cite

Background and objectiveGeneral practitioners (GPs) play a central role in healthcare, serving as the first point of contact, making appropriate referrals and coordinating care for chronic conditions such as heart failure (HF). We sought to determine healthcare use by people with HF in primary care. MethodsIn this Study of Heart failure in the Australian Primary carE setting (SHAPE), we analysed records of 1.93 million adult patients who attended a total of 43 practices between 1 July 2013 and 30 June 2018. We identified and examined the data of 20,219 patients with HF to describe the frequency of visits and use of Medicare Benefits Schedule items. ResultsPatients with HF saw GPs 14.4 times per annum on average; 59.5% had a General Practice Management Plan (GPMP), 2.9% of GPMPs were reviewed annually or more frequently, and 46.8% of patients had been referred to a cardiologist. A total of 3761 had coexisting anxiety or depression, and of these 37.1% had a mental health plan. DiscussionPatients with HF visit their GP frequently, with many not reaching guideline therapy nor referred to cardiologists. Low use of care planning and reviews presents an opportunity for GPs to improve care.

show abstract

Section: Resultsmentioning

confidence: 79%

Healthcare services use by patients with heart failure in Australia: Findings from the SHAPE study

Audehm

Neville²,

Piazza³

et al. 2022

Aust J Gen Pract

Self Cite

View full text Add to dashboard Cite

show abstract

“…An alarming rise in relatively young people and in countries with low socio‐demographic index is probably related to an increase in risk factors 5,6 . In addition, there has been a clear transition towards HFpEF due to an improvement in the recognition of the disorder but also its relationship to obesity and the ageing of the population 4,7–10 .…”

Section: Epidemiologymentioning

confidence: 99%

Heart failure: an update from the last years and a look at the near future

et al. 2022

View full text Add to dashboard Cite

In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use. Concurrent use of potassium-lowering agents may counteract hyperkalaemia and facilitate renin-angiotensin-aldosterone system inhibitor implementations. The results of the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trial were confirmed by the Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER) trial, and we now have, for the first time, evidence for treatment of also patients with HF with preserved ejection fraction. In a pre-specified meta-analysis of major randomized controlled trials, sodium-glucose co-transporter-2 inhibitors reduced all-cause mortality, cardiovascular (CV) mortality, and HF hospitalization in the patients with HF regardless of left ventricular ejection fraction. Other steps forward have occurred in the treatment of decompensated HF. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR) trial showed that the addition of intravenous acetazolamide to loop diuretics leads to greater decongestion vs. placebo. The addition of hydrochlorothiazide to loop diuretics was evaluated in the CLOROTIC trial. Torasemide did not change outcomes, compared with furosemide, in TRANSFORM-HF. Ferric derisomaltose had an effect on the primary outcome of CV mortality or HF rehospitalizations in IRONMAN (rate ratio 0.82; 95% confidence interval 0.66-1.02; P = 0.070). Further options for the treatment of HF, including device therapies, cardiac contractility modulation, and percutaneous treatment of valvulopathies, are summarized in this article.

show abstract

“…Prevalence of HF in Australia between 2013 and 2018 showed more men in the age range from 55 to 84 years than women, and the total number of women with HF continued to increase with age, peaking only in the highest age bracket (≥85 years). 26 However, these studies did not provide a detailed analysis of HF incidence by sex, age, and year at a time. In our study, the incidence of HF by gender, age, and year is presented intuitively at a glance using simple graphs, and it can help to understand the changing pattern over time and the differ- Intuitive patterns showing distinct sexual differences ence between both genders.…”

Section: Discussionmentioning

confidence: 99%

The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea

Chun,

Pak,

Kim

et al. 2023

ESC Heart Failure

View full text Add to dashboard Cite

AimsThe prevalence and incidence rate of heart failure (HF) continues to increase along with the aging of the population and the increase of ischaemic heart disease. The morbidity and mortality of HF are also on the rise in the industrialized countries; it can be a great public health problem. A detailed and accurate analysis of the demographical incidence and prevalence of HF is an important first step in predicting the occurrence of the disease in the future and proper preparing for prevention. Here, we aimed to analyse the annual prevalence and incidence of HF by gender and age using long‐term national health insurance service data in the Republic of Korea.Methods and resultsA total of 47 243 patients newly diagnosed with HF between 2006 and 2015 among nationally representative random subjects of 1 000 000 were included. The data of age and gender were analysed by year, and the total population information of the Ministry of Land, Infrastructure, and Transport of Korea was referred to compare the data of HF patients with the total population (2008–15). Over the decade from 2006 to 2015, the prevalence of HF patients showed tendency of increase (P < 0.001). The overall incidence rate was also gradually increasing (P < 0.001), but in women, it tended to decrease gradually. Women significantly accounted higher than the male group in incidence of HF over the period (54.6% vs. 45.4%, P < 0.001). The mean age at the time of diagnosis gradually increased (P = 0.002 for total, P = 0.001 for each gender). Total incidence was highest in 70s (27.22%), but males were the most in their 60s and females were in their 70s. Analysis of annual trend by age and gender distribution of HF incidence in men presented highest in the 50s–70s with a similar pattern annually, and the incidence is increasing more recently. Different from that of men, in the case of women, the incidence gradually increased with age in a similar annual pattern, peaking in their 70s and gradually decreasing in recent years.ConclusionsThe prevalence and incidence of HF are gradually increasing. It increased rapidly in their 50s and older. It showed an increased incidence of HF especially in men between their 50s and 70s, and more observation and caution for the management of the risk factors may be needed to prevent HF in the male group.

show abstract

Epidemiology of heart failure: Study of Heart failure in the Australian Primary carE setting (SHAPE)

Cited by 9 publications

References 8 publications

Healthcare services use by patients with heart failure in Australia: Findings from the SHAPE study

Healthcare services use by patients with heart failure in Australia: Findings from the SHAPE study

Heart failure: an update from the last years and a look at the near future

The characteristic large‐scale annual analysis by gender and age in heart failure patients: cohort for 10 years in Korea

Contact Info

Product

Resources

About